Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* Chronic HCV infection (≥ 6 months)~* Serum HCV RNA of ≥ 1 × 104 IU/mL are documented~* Hepatitis C virus GT1~* Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or host-targeting antivirals for HCV~* Non-cirrhosis patients: Non-cirrhosis is defined (1)Fibroscan defined as: ˂ 14.6 kPa during screening period, or liver biopsy determined 1 year before recruiting (Metavir score ˂ 3);(2) during screening period 9.6\<Fibroscan indicator ≤12.9, liver biopsy need to confirm non-cirrhosis.~* Others as specified in the detailed protocol~Exclusion Criteria:~* Patients with Fibroscan detection value \> 12.9 kPa, or histologic examination for liver cirrhosis patients~* Presence or history of non-hepatitis C chronic liver disease (e.g. HH, AIH, Wilson's disease, α1 antitrypsin deficiency, drug- or toxin-induced liver disease)~* History of liver cell cancer, or suspected hepatocellular carcinoma (HCC) patients before or during screening , or imaging studies found suspicious nodules, or AFP \> 50 ng/mL~* Positive hepatitis A antibody，positive hepatitis B surface antigen，HIV antibody~* Presence or history of nervous system diseases and/or mental illness, inability to control oneself or express oneself.~* Patients with obvious cardiovascular dysfunction~* Pregnant or nursing female, nor unwilling to take reliable contraception~* Others as specified in the detailed protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danoprevir, Ritonavir, Peg-IFN,RBV (Type: EXPERIMENTAL): Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).